cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Simulations Plus Inc
5 own
4 watching
Current Price
$40.43
$-1.31
(-3.14%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
821.29M
52-Week High
52-Week High
67.5899
52-Week Low
52-Week Low
32.575
Average Volume
Average Volume
0.07M
Dividend Yield
Dividend Yield
0.004426
P/E Ratio
P/E Ratio
114.9962
iconMarket Capitalization821.29M
icon52-Week High67.5899
icon52-Week Low32.575
iconAverage Volume0.07M
iconDividend Yield0.004426
iconP/E Ratio114.9962
What does the Simulations Plus Inc do?
Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; and KIWI, a cloud-based Web application, which organizes, processes, maintains, and communicates the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program. Further, the company provides consulting services ranging from early drug discovery through preclinical and clinical trial data analysis, and for submissions to regulatory agencies; and population modeling and simulation contract research services for the pharmaceutical and biotechnology industries. Additionally, it offers pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, and food companies. The company distributes its products and services worldwide. Simulations Plus, Inc. was founded in 1996 and is headquartered in Lancaster, California.
Read More
How much money does Simulations Plus Inc make?
News & Events about Simulations Plus Inc.
Business Wire
28days ago
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym version X (DSX) Beta, the latest version of its flagship quantitative...
Ticker Report
1month ago
Simulations Plus, Inc. (NASDAQ:SLP Get Rating) Director Walter S. Woltosz sold 20,000 shares of the firms stock in a transaction that occurred on Wednesday, December 28th. The shares were sold at an average price of $36.15, for a total transaction of $723,000.00. Following the ...
Business Wire
2 months ago
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that, through a joint proposal with the University of Baths Department of Life Sciences, it has been awarded a new funded grant from the...
Business Wire
3 months ago
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Gustavo Mendes Lima Santos has joined its Regulatory Affairs team on a one-year fellowship appointment. Mendes Lima Santos will...
Business Wire
4 months ago
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of version 9.8.3 of its flagship physiologically based biopharmaceutics (PBBM) / pharmacokinetics (PBPK) modeling platform...
Frequently Asked Questions
Frequently Asked Questions
What is Simulations Plus Inc share price today?
plus_minus_icon
Can Indians buy Simulations Plus Inc shares?
plus_minus_icon
How can I buy Simulations Plus Inc shares from India?
plus_minus_icon
Can Fractional shares of Simulations Plus Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Simulations Plus Inc stocks?
plus_minus_icon
What is today’s traded volume of Simulations Plus Inc?
plus_minus_icon
What is today’s market capitalisation of Simulations Plus Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Simulations Plus Inc?
plus_minus_icon
What percentage is Simulations Plus Inc down from its 52-Week High?
plus_minus_icon
What percentage is Simulations Plus Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$40.43
$-1.31
(-3.14%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00